Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2021

01-01-2021 | Breast Cancer | Epidemiology

Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database

Authors: Hannah Grace Abraham, Yaoxuan Xia, Bhramar Mukherjee, Sofia Diana Merajver

Published in: Breast Cancer Research and Treatment | Issue 1/2021

Login to get access

Abstract

Purpose

Inflammatory breast cancer (IBC) is an aggressive variant characterized by erythema, edema, and “peau d’orange” of the skin progressing within 6 months. We assessed the incidence and survival of IBC in the US over four decades.

Methods

Using SEER*Stat, a case list of IBC patients diagnosed between 1973 and 2015 (n = 29,718) was extracted from SEER 18 registries by using a combination of morphology, stage, and extent of disease criteria. M1 and M0 patients were included. Age-adjusted incidence rates, relative survival rates, and mean survival time were calculated. Significance was determined as non-overlapping 95% confidence intervals.

Results

The overall incidence of IBC from 1973 to 2015 is 2.76 (2.73, 2.79) cases per 100,000 people, with white patients having an incidence rate of 2.63 (2.60, 2.67), black patients 4.52 (4.39, 4.65), and patients of other race 1.84 (1.76, 1.93). The overall IBC relative 5-year survival rate is 40.5% (39.0%, 42.0%), 42.5% (40.7%, 44.3%), and 29.9% (26.6%, 33.3%) for white patients and black patients, respectively. Patients diagnosed in 1978–1982 have a mean survival time of 62.3 (52.0, 72.6) months, while those diagnosed in 2008–2012 have mean survival time of 99.4 (96.4, 102.4) months. There is no significant difference in survival time between T4D patients and patients with other T staging and extent of disease coding consistent with clinical IBC presentation.

Conclusions

IBC survival has increased over four decades. Despite the improvement in survival for all racial groups, a persistent survival disparity that has not narrowed over two decades remains between white and black patients.
Appendix
Available only for authorised users
Literature
2.
go back to reference Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82(12):2366–2372CrossRef Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82(12):2366–2372CrossRef
9.
go back to reference Levine PH, Steinhorn SC, Ries LG, Aron JL (1985) Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 74:291–297PubMed Levine PH, Steinhorn SC, Ries LG, Aron JL (1985) Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 74:291–297PubMed
13.
go back to reference Kaye DH, D. a Freedman, (2011) Reference guide on statistics. In: Kaye DH, Freedman DA (eds) Reference manual on science evidence, 3rd edn. The National Academies Press, Washington D.C, p 211 Kaye DH, D. a Freedman, (2011) Reference guide on statistics. In: Kaye DH, Freedman DA (eds) Reference manual on science evidence, 3rd edn. The National Academies Press, Washington D.C, p 211
14.
go back to reference Ederer F, Heise H (1959) Instructions to IBM 650 programmers in processing survival computations. Methodological note No.10. End results evaluation section. Bethesda, MD Ederer F, Heise H (1959) Instructions to IBM 650 programmers in processing survival computations. Methodological note No.10. End results evaluation section. Bethesda, MD
15.
go back to reference M. Greenwood (1926) A report on the natural duration of cancer. Reports on public health and medical subjects. Ministry of Health, London H M S O. M. Greenwood (1926) A report on the natural duration of cancer. Reports on public health and medical subjects. Ministry of Health, London H M S O.
16.
go back to reference Brenner H, Gefeller O (1996) An alternative approach to monitoring cancer patient survival. Cancer 78:2004–2010CrossRef Brenner H, Gefeller O (1996) An alternative approach to monitoring cancer patient survival. Cancer 78:2004–2010CrossRef
17.
go back to reference Efron B (1979) Bootstrap methods another look at the Jackknife. In: Kotz S, Johnson NL (eds) Breakthroughs in statistics. Series in statistics (Perspectives in statistics). Springer, New York, pp 569–593 Efron B (1979) Bootstrap methods another look at the Jackknife. In: Kotz S, Johnson NL (eds) Breakthroughs in statistics. Series in statistics (Perspectives in statistics). Springer, New York, pp 569–593
20.
go back to reference Noone A et al (2017) SEER cancer statistics review, 1975–2015. National Cancer Institute, Bethesda, MD Noone A et al (2017) SEER cancer statistics review, 1975–2015. National Cancer Institute, Bethesda, MD
21.
go back to reference DeSantis C, Miller K, Sauer AG, Jemal A, Siegel R (2019) Cancer statistics for African Americans, 2019. CA Cancer J Clin 69(3):211–233CrossRef DeSantis C, Miller K, Sauer AG, Jemal A, Siegel R (2019) Cancer statistics for African Americans, 2019. CA Cancer J Clin 69(3):211–233CrossRef
22.
go back to reference DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRef DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRef
Metadata
Title
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database
Authors
Hannah Grace Abraham
Yaoxuan Xia
Bhramar Mukherjee
Sofia Diana Merajver
Publication date
01-01-2021
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05938-2

Other articles of this Issue 1/2021

Breast Cancer Research and Treatment 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine